Skip to main content
Lepu Biopharma Co., Ltd. logo

Lepu Biopharma Co., Ltd. — Investor Relations & Filings

Ticker · 2157 ISIN · CNE100004SM4 HKEX Manufacturing
Open in API
Filings indexed 240 across all filing types
Latest filing 2022-09-01 Proxy Solicitation & In…
Country HK Hong Kong
Listing HKEX 2157

About Lepu Biopharma Co., Ltd.

http://www.lepubiopharma.com

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company dedicated exclusively to the research and development of oncology therapeutics. The company focuses on advanced tumor treatment modalities, including targeted therapy and cancer immunotherapy. Its strategically built product pipeline encompasses a range of candidate drugs, notably Antibody-Drug Conjugates (ADCs), immunotherapies, and oncolytic virus drugs, with assets spanning clinical and preclinical development stages. Lepu Biopharma leverages its proprietary ADC technology platform to drive the development of innovative treatments. The company pursues domestic commercialization through dedicated sales infrastructure while actively seeking global market access, particularly in the US and European markets, via strategic partnerships and out-licensing agreements for its drug candidates.

Recent filings

Filing Released Lang Actions
PROXY FORM FOR USE AT THE 2022 FIRST CLASS MEETING OF H SHAREHOLDERS
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a proxy form for use at a shareholders' meeting, specifically the 2022 first class meeting of H shareholders of Lepu Biopharma Co., Ltd. It contains instructions for appointing a proxy to vote on various resolutions related to share issuance, dividend plans, and amendments to articles. The content is focused on soliciting votes and providing voting instructions rather than reporting financial results or company performance. This type of document is used to provide information and request votes from shareholders for a meeting, which fits the definition of a Proxy Solicitation & Information Statement (PSI). The document length is 9047 characters, which is consistent with a detailed proxy form rather than a brief announcement or a full report. Therefore, the appropriate classification is PSI.
2022-09-01 English
PROXY FORM FOR USE AT THE 2022 FIRST EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a proxy form for use at the 2022 first extraordinary general meeting of Lepu Biopharma Co., Ltd. It contains detailed instructions for shareholders to appoint proxies and vote on various resolutions related to share issuance, amendments to company rules, and other governance matters. The content is focused on facilitating shareholder voting at a general meeting rather than presenting financial results, management discussion, or audit information. It is not a report or announcement of financial results, nor is it a regulatory filing or certification. The document is clearly related to shareholder meeting materials, specifically proxy solicitation for voting purposes at an extraordinary general meeting. Therefore, the most appropriate classification is Proxy Solicitation & Information Statement (PSI).
2022-09-01 English
(1) PROPOSED ISSUE OF A SHARES AND LISTING ON THE SCI-TECH BOARD AND OTHER ANCILLARY RESOLUTIONS&#x3b; (2) PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED ISSUE OF A SHARES&#x3b; (3) UNC
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a circular from Lepu Biopharma Co., Ltd. concerning the proposed issue of A shares and listing on the Sci-Tech Board, proposed amendments to the articles, uncovered deficit, and notices of an Extraordinary General Meeting (EGM) and Class Meetings. It includes detailed information about the meeting, proxy forms, precautionary measures, and appendices related to the resolutions to be considered. The document is not a financial report but rather a comprehensive meeting circular with notices and proposals for shareholder approval. This fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings such as EGMs.
2022-09-01 English
NOTICE OF THE 2022 FIRST CLASS MEETING OF DOMESTIC SHAREHOLDERS
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice of a shareholders' meeting specifically for the 2022 first class meeting of domestic shareholders of Lepu Biopharma Co., Ltd. It includes detailed agenda items such as approval of a new share issuance (A Shares), authorization to the board for handling the issuance, use of proceeds, dividend plans, amendments to articles, and related party transactions. The document is a formal notice calling for a shareholders meeting to vote on these resolutions, not the results of the vote or a report of the meeting outcomes. It is not a full financial report, earnings release, nor a proxy solicitation document. The content aligns with a formal meeting notice and agenda for a shareholder meeting rather than a report or announcement of voting results. Therefore, the classification best fitting this document is a Proxy Solicitation & Information Statement (PSI), as it provides information to shareholders to solicit their votes at the meeting.
2022-09-01 English
NOTICE OF THE 2022 FIRST CLASS MEETING OF H SHAREHOLDERS
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice for the 2022 first class meeting of H shareholders of Lepu Biopharma Co., Ltd. It details the agenda for the meeting, including resolutions to approve a proposed issue of A shares, authorization to the board for handling related matters, use of proceeds, dividend plans, amendments to articles, and related party transactions. The document is a formal announcement inviting shareholders to attend and vote on these matters, including procedural details about proxy voting and meeting logistics. It does not contain financial statements, audit opinions, or detailed financial analysis. It is not a report but a notice of a shareholder meeting with proposed resolutions. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-09-01 English
NOTICE OF THE 2022 FIRST EXTRAORDINARY GENERAL MEETING
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a detailed notice of an Extraordinary General Meeting (EGM) for Lepu Biopharma Co., Ltd. It includes the agenda items for shareholder approval, such as the proposed issuance of new A Shares, authorization to the Board for handling related matters, use of proceeds, dividend plans, amendments to articles, and other governance-related resolutions. The document is a formal meeting notice with resolutions to be voted on, not a report or announcement of results. It is not a financial report, earnings release, or regulatory filing but a notice for a shareholder meeting. Therefore, the appropriate classification is 'Declaration of Voting Results & Voting Rights Announcements (DVA)' since it relates to shareholder meeting resolutions and voting matters, although it is a notice prior to the meeting, the closest category fitting the content is DVA as it deals with shareholder voting matters. Confidence is high given the explicit meeting notice and resolution details.
2022-09-01 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.